Obesity may not be the only factor that causes hyperandogenemia and anovulation because some obese women are fertile and do not have hyperandrogenism. The aim of study is to find out whether there is any link between tamoxifen therapy with ovarian cyst complaining with body weight & associated symptoms. A prospective clinical study diagnosis of breast cancer, and complete surgical intervention and cytotoxic therapy a pelvic ultrasound examination were performed in all these study cases, after tamoxifen administration was started. Both ovarian conditions, Ovarian cysts were identified as sonolucencies in the ovary with a diameter of >20 mm in the postmenopausal and >25 mm in the premenopausal patient group. Endometrial thickness, uterus was scanned in the longitudinal plane. The double-layer endometrial thickness was measured at the widest point between the endometrial-myometrial interfaces in the sagittal plane, ovarian appearance size, and condition were measured. RT ovarian cystic and increase body weight during tamoxifen therapy, while LT ovarian cystic formation had a relation with increase body weight during tamoxifen therapy. there is relation between ovarian cysts in both ovaries and abdominal pain, vaginal bleeding & vaginal secretion, with the relation between the incidence of RT ovarian cysts & relation with associated symptoms, while the relation between the incidence of LT ovarian cyst & associated symptoms. Ovarian cysts are common complications of tamoxifen treatment. Ovarian cysts can develop in both premenopausal and postmenopausal patients receiving tamoxifen for breast cancer so should be under close ultra-sonographic surveillance.